We report the case of an 80-year-old female suffering from pancreatic cancer who developed severe non-alcoholic steatohepatitis (NASH) resulting in fatal hepatic failure after anti-cancer chemotherapy with gemcitabine. Hepatic encephalopathy appeared one year after the chemotherapy and the patient developed progressive liver failure and eventually died. Radiological examination showed severe fatty liver.
INTRODUCTION
Steatohepatitis can be categorized as alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH), based on its etiopathogenesis. 1 Ludwig primarily introduced NASH to describe a form of liver disease that is histologically indistinguishable from ASH, but occurs in patients that do not consume excess alcohol. 2 Recently, NASH has been recognized as a hepatic manifestation of metabolic syndrome, associated with obesity, diabetic mellitus, and hyperlipidemia.
This type of NASH is known as primary NASH. 1 In contrast, secondary NASH is caused by jejunoileal bypass surgery, total parenteral nutrition, drugs, and industrial toxins. As for drug-induced steatohepatitis, consistent with the term 'NASH', the term "chemotherapy associated steatohepatitis" (CASH) has been proposed. Cases of drug-induced liver damage as well as the kinds of causative drugs have been increasing recently, but drug-induced liver injury showing the clinicopathological features of steatohepatitis is very rare. 2 This is because in complex medical conditions, the diagnosis may be confounding, and the potential hepatotoxicity of chemotherapeutic agents may be easily overlooked.
In this report, a fatal case of CASH which was possibly associated with anti-cancer chemotherapy using gemcitabine is introduced. Such case reports are extremely rare.
CASE PRESENTATION

Clinical history
The patient was an 80-year-old Japanese female. She had a history of hysterectomy for hysteromyoma, cholecystectomy for cholecystolithiasis, Basedow's disease, and autonomic dystonia and had regularly gone to the hospital to treat autonomic dystonia.
She was not a drinker. CT scan imaging revealed the presence of mass formation suggesting pancreatic cancer in the pancreatic head and the absence of definite fatty liver (Fig.1A ) and the patient was admitted to initial hospital for the treatment in July 
Histology of liver necropsy
Histopathological examination of the liver revealed a pan-lobular fatty change, predominantly macrovesicular, involving approximately 90% of lobules (Fig.3) .
Ballooning degeneration and necrosis of hepatocytes accompanying neutrophil infiltration and bile plugs were found in zone 3 admixed with steatosis (Fig.4) . These ballooned hepatocytes contained typical Mallory bodies consisting of dense and ropy hyaline (Fig.4) . Portal tracts were fibrously expanded, and perivenular and (Fig.5) . In portal tracts, mild infiltration of lymphocytes and neutrophils and mild interface hepatitis were found. We made a diagnosis of NASH (Grade 3, Stage 3), 3 probably CASH associated with gemcitabine.
DISCUSSION
Recently, cases of NASH are increasing and its etiology and mechanisms have been examined. Moreover, cases of drug-induced liver injury are also increasing and many drugs causing hepatic damage have been reported. Steatosis is one common pathological feature of drug-induced liver injury, but cases of steatohepatitis are very rare. 2 The liver histology of the patient described in this report was typical of steatohepatitis and alcohol history was not applicable in this case. Therefore, we made a diagnosis of NASH. In general, ASH and NASH are thought to have a similar histology. 4 In fact, the two can be indistinguishable in terms of macrovesicular fatty change, fibers, and hepatocellular ballooning. However, detailed histological differences between ASH and NASH, particularly ASH and primary NASH, have been reported. For example, in cases of ASH, a typical Mallory body is found, but in cases of primary NASH, an atypical Mallory body that is 'poorly formed' and lacks the dense ropy quality of hyaline is seen. 5 Moreover, neutrophil infiltration and hepatocellular necrosis are thought to be prominent in ASH, compared with NASH.
Patients with ASH, therefore, generally show severe liver dysfunction. The histological features of secondary NASH including CASH depend on the etiology and drugs involved.
Several drugs including nifedipine, 6 tamoxifen, 2 estrogen, 2 corticosteroid, 7 and methotrexate 8 have been reported as causative of NASH. Among them, the anti-estrogen drug tamoxifen, is most well-known. Methotrexate, an antimetabolite, has also been reported as a reagent causing NASH and liver fibrosis. 8 In general, antimetabolites show hepatotoxicity. Gemcitabine (Gemzar®) is a novel analogue of deoxycytidine which inhibits DNA synthesis and acts as an antimetabolite with broad-spectrum anti-cancer activity including against pancreatic cancer. 9 It is used as a standard medication for many cancers including pancreatic cancer and non-small cell lung cancer. Hepatotoxicity due to gemcitabine is known, but has repeatedly been described as a slight, transient, asymptomatic, and rapidly reversible elevation of AST and ALT levels. 10, 11 Therefore, gemcitabine does not have severe toxicity; however, fatal cases of liver injury involving veno-occlusive diseases 12 and cholestatic liver failure 13, 14 that developed after treatment with gemcitabine have been reported. 13, 15 This patient had obesity (BMI 29 at peak) and mild impaired glucose tolerance, but no fatty liver was found before the chemotherapy. Because the radiological findings of pancreatic cancer did not changed before and after the chemotherapy and no liver metastasis was not found, cancer-associated liver dysfunction causing the fatal course was unlikely in this case. Intrahepatic cholestasis as well as steatosis, moreover, was also found in the liver, suggesting the drug-associated liver injury.
Therefore, the possibilities of other factors causing steatohepatitis are raised in this case, but the association of chemotherapy is likely in the pathogenesis of steatohepatitis. As mentioned above, two fatal cases of cholestatic liver failure related to gemcitabine therapy have been reported. 13, 14 The reason why this patient died of hepatic failure is unknown, but we speculated that the combined hepatocellular damage associated with steatohepatitis and cholestasis caused hepatic decompensation.
The histological features of secondary NASH including CASH depend on the etiology and drugs involved. Several drugs including methotrexate, tamoxifen, and aminodarone, initially induce mitochondrial dysfunction through an impairment of beta-oxidation, which plays a central role in the pathogenesis of drug-induced steatosis and steatohepatitis and also in that of alcoholic cytotoxicity. 2 Therefore, drug-induced steatohepatitis could show an ASH-like histology. This case also showed ASH-like histological features; typical Mallory bodies, prominent
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To our knowledge, this is the first case of possibly gemcitabine-induced steatohepatitis encountered during the treatment of pancreatic cancer. Recently, drug-induced hepatic damage has been broadly recognized, but as a special type of liver injury, physicians treating patients with this antitumor drug should be alert to the possibility of CASH. 
